The advent ofbisphosphonares advanced therapy for Paget's disease, but more effec.-tive and convenient agents are needed to increase adherence. Zoledronic acid, a bisphosphonate administered as a single intraVenous infusion, might meet these needs.
METHODS
In two identical, randomized, double-blind, actively controlled trials of6 months' duration, we compared one 15-minute infusion of 5 mgof zoledronicacid with 60 days of oral risedronate (30 mg per day). The primary efficacy end pointwas the rate of therapeutic response at six months, defined as a nonnalization of alkaline phosphatase levels or a reduction ofat least 75 percent in the tot.al alkaline phosphatase excess. The results of the studies were pooled.
RUULTS
At six months, 96.0 percent of patients receiving zoledronic acid had a therapeutic response (169 of176), as compared with 74.3 percent of patients receiving risedronate (U7 of 171, P<0.001). Alkaline phosphatase levels noonalized in 88.6 percent of patients in the zoledronic acid group and 57 .9 percent of patients in the risedronate group (P<0.001). Zoledronic acid was associated with a shorter median time to a first therapeutic response (64 vs. 89 days, P<0.001). Higher response rates in the zoledronic acid group were consistentacross all demographic, disease-severity, and treatment-history subgroups and with changes in other bone-turnover markers. The physical-component summary score of the Medical Outcomes Study 36-item Short-Form General Health Survey, a measure of the quality of life, increased significantly from baseline at both three and six months in the zoledronic acid group and differed significantly from those in the risedronate group at three months. Pain scores improved in both groups. During post-trial follow-up (median, 190 days), 21 of82 patients in the risedronat.e group had a loss of therapeutic response, as compared with 1 of113 patients in the zoledronic acid group (P<0.001).
CONCLUSIONS
A single infusion of zoledronic acid produces more rapid, more complete, and more sustained responses in Paget's disease than does daily treatment with risedronate.
N INCL J "'ED 353;9 WWW.N£J ... ,ORC SEPTE ... l [A 1, 2005 ZOL.llDRONJC ACID .POll PAGET'S DISEASE P AGET'S DISEASE O.F .BONE rs CHARAC- t.erized by a dramatic increase in bone turnover (both formation and resorption) at one or more sites. Measurement of biochemical markers of bone turnover is used to assess disease activity and monitor the response to therapy. About 2 per--cent of the U.S population older than 60 years of age have Paget's disease, 1 as do up to 6 or 7 percent of the elderly population in western Europe. 2 The bone pain, skeletal defonnity, pathologic fractures, secondary arthritis, neurologic complications, and deafuess that may accompany this disease contribute to substantial morbidity in the older population.
Bisphosphonate therapy is the most commonly used treatment for Paget's disease, often normalizing biochemical markers of bone turnover and resulting in the replacement of chaotic woven bone with nonnaJ Jame liar bone. 3 Bisphosphonates may also reduce bone pain. 4 Currently used oral bisphosphonates require daily oral dosing for two to six months, with patients required to &st before and after tteabnent because of the very low bioavailability of the drugs and to remain upright for at least 30 minutes after dosing to reduce the risk of upper gastrointestinal complications. The intravenous bisphosphonate pamidronate is also used but is inconvenient for patients because it is usually given as a series of slow intravenous infusions each lasting a few hours, requiring multiple visits.
The development of convenient, more effective, and longer-lasting agents might address these problems.
Of the bisphosphonates that have entered clinical trials, zoledronic acid was very effective in preclinical modets. 5 • 7 Itis administered as a single 15-minute infusion and has effects on bone mineral density in postmenopausal women similar to those afforded by 12 months of oral bisphosphonate therapy. 8 This medication offers the possibility of a substantial increase in the convenience oftteatmentand adherence, which together with its great· er efficacy, may increase response rates and the duration of remission. We compared the effects of zoledronic acid with those of risedronate, a leading bisphosphonate in current use, on biochemical indexes of disease activity and the quality of life.
METHODS
from North America, Europe, and Australasia. One study also included patients from South Africa. Although the trials were independent, each protocol called for pooling of the results in a joint analysis.
PATIENTS
A total of 357 men and women who were older than 30 years of age and had radiologically confirmed Paget's disease of bone were studied at 76 centers in 10 countries. With the exception of four patients, all had alkaline phosphatase levels that were more than twice the upper limit of normal. Exclusion criteria included a serum 25-hydroxyvitamin O level ofless than 15 ng per milliliter (37 nmol per liter); primary hyperparathyroidism; evidence ofhepatic or renal disease; a history ofuveitis, iritis, upper gasttointestinal disorders that might interfere with adherence to the protocol, or diabetic nephropathy or retinopathy; and use of therapy specifically for Paget's disease in the preceding 180 days.
The institutional review board of each participating center approved the protocol, and all patients gave written informed consent
TREATMENT
Patients were randomly assigned in a double-blind fashion through an interactive voice-response system to receive either a 5-mg infusion ofaoledronic acid over a 15-minute period followed by placebo tablets or a saline infusion followed by 30 mg of risedronate per day for 60 days. The volume of all infusions was 105 m1. All patients received 1 g of caldum per day and 400 to 1000 U of calciferol per day.
STUDY END POINTS
The primary end point was the proportion of patients who had a therapeutic response, defined as nonnalization of the alkaline phosphatase level or a red.uction of at least 75 percent in the alkaline phosphatase excess (the difference from the midpoint of the reference range) at six months. 
SAFETV ASSESSMENTS
Physical examinations, hematologic tests, and serum chemical tests were performed regularly throughout the su•month study. Serum creatinine and urinary protein were measured 9 to 11 days after intravenous dosing.
STATISTICAL ANALYSIS
Each study had a statistical power of80 percent to demonstrate the noninferiority of zoledronic acid relative to risedronatewith respect to the proportion of patients who had a therapeutic response at six months. Assuming a dropout rate of approximate· Iy 10 percent per study, we estimated that 88 patients were needed in each group (176 patients total) to evaluate noninferiority. Noninferioritywas estab· lished if the one-sided 97 .5 percent confidence interval for the absolute difference between zoledronic acid and risedronateexceeded 16 percent In that case, superiority was evaluated with the use of a logistic-regression model that included tteatment and the baseline alkaline phosphatase level as ex· planatory variables.
All efficacy variables, except the time to a ther· apeutic response, were analyzed according to the modified intention·to-tteat principle, which required patients to have a baseline and at least one post-baseline measurement of alkaline phosphatase. The time to a therapeutic response was analyzed according to the intention-to-treat principle and therefore included all randomized patients.
Missing values for the primary efficacy variable were imputed by canying the last obseivation forward.
Differences between groups in secondary or explomtory efficacy variables were evaluated by means oflogistic regression, analysis of covariance, or Cox regression, where appropriate. For secondary efficacy variables, a two-sided Pvalue of 0.05 was considered to indicate st.atistical significance. A dosed testing procedure was used to control the type I error rate of these comparisons. Comparisons within groups were made with t-tests.
Results are based on pooled data from the two studies. All parametric models included study as an explanatory variable. Data are given as means ±SD unless otherwise specified.
The protocol was designed by the sponsor and reviewed and modified by the investigators. Data management and statistical analyses were per~ formed by the sponsor. The publications committee (Drs. Reid, Miller, Lyles, Fraser, Brown, aod Hosking) had full access to and interpreted the data. Drs. ~id and Miller wrote the article and vouch for the accuracy and completeness of the reported information.
RESULTS

PATIENTS
A total of182 patients were enrolled in the zoledron· ic acid group and 175 in the nsedronate group, of whom 1n and 172 patients, respectively, received the study drug (Fig. 1) . Patients' characteristics at baseline are shown in Table 1 . Adherence exceeded 90 percent in 98.3 percent of patients in the risedronate group and 93.2 percent of patients in the zoledronic acid group, as detmnined by pill counts.
SERUM ALKALINE PHOSPHATASE
Serum allciline phosphat.ase levels ( Fig. 2A) showed a more rapid and marked reduction in the zoledronic acid group than in the risedronate group. After 10 days, the rates of therapeutic response were consistently higher in the zoledronic acid group than in the risedronate group, reaching 96.0 percent and 74.3 percent respectively, at six months {P<0.001) (Fig. 2B) The populations included in the effk.acy analysis consisted of patiencs who received at least one dose of study medication and had a baseline and at least one post-baseline measurement of alkaline phosphatase. risedronate group (P<0.001). The higher rates of response in the zoledronic acid group were independent of age, sex, baseline alkaline phosphatase level, and the presence or absence of previous ther· apy for Paget's disease. The rares of normalization of the alkaline phosphatase level also differed significantly between groups (P<0.001} at all times from one month onward (Fig. 2C ).
OTHER BIOCHEMICAL MAllKERS
OF BONE TURNOVEIII
Serum levels of the N·terrninal propeptide of type I collagen, another marker of osteoblast activity, showed a pattern similar to that of alkaline phosphatase, but the response tended to be greater, probably because the serum level of the N·tenninal propeptide of type I collagen is a more specific index of osteoblast activity. (Fig. 3A) . Bone resorption, assessed in terms of the serum level of the j:JC-telopeptide of type I collagen (Fig. 3B ) and the ratio ofurinary aC-telopeptide of type I collagen to creatinine (Fig. 3C) , showed greater reductions with zoledronic acid than with risedronate at all times. Consistent with the osteodast's being the primaiy target ofbisphosphonates, these markers responded more rapidly than the N-termina.l propeptide of type I collagen or alkaline phosphatase, and the very rapid decrease in resorption in response to an intravenous bisphosphonate was also :j: Scores on each SF-36 scale can range from Oto 100, with higher scores indicating a better quality oflife.
QUALITY OF LlfE
In the zoledronic acid group, mean scores for ea.ch of the eight components of the SF-36 trended upward at both three and six months, suggesting improvements in the quality of life, whereas the responses were more mixed in the risedronate group (Fig. 4) . The zoledronic acid group had a significantly greater improvement than the risedronate group in physical functioning at three months and general health at six months. The zoledronic acid group bad a significant improvement from baseline scores in the physical-component summary score at both three and six months, and these chang~ were significantly greater than those in the risedronate group at three months. Multivariate tests for all components of the SF-36 suggested the superiority of zoledronic acid.
BONE IIOPS\'
Transiliac bone biopsies were performed in 22 patients, 12 taking zoledronic acid and 10 talcing risedronate. Bleven biopsy specimens were incom-
ZOLEDJtONIC ACID FOIi. PAGET 'S DJSl!ASE plete, and one included only remnants of iliac epiphysis, but these showed no abnormality on qualitative examination. Of the 10 biopsy specimens that could be evaluated, 2 came from sit.es of Paget's disease (from one patient in each group) and were otherwise normal, apart from increased mineralizing surface in the patient in the risedronare group. The remaining eight biopsy specimens from nonpagetic bone were similar, except that the extent of the mineralizing surface was below the reference range in the zoledronic acid group (P=0.04 for the comparison with the risedronate group}. There was no evidence of adynamic bone or qualitative abnormalities ofbone formation in any biopsy specimen.
ADVERSE l!YENTS
No deaths occurred. The numbers of patients with adverse even~ (146 in the zoledronic acid group and 133 in the risedronar.e group) and serious adverse events (9 in the zoledronic acid group and 11 in the risedronate group) were similar in the two groups. Because there was a marked clustering of adverse events in the first three days after intrave--nous drug administration, the data were tabulated separately for this period (Table 2 ). In the first three days, the zoledronic acid group had twice the number ofadverse events as the risedronar.e group (P<0.001), and these were principally the influenza-like symptoms that are known to oc--cu.r in associadon with the intravenous use of nitrogen-containing bisphosphonates. These symptoms were mild t.o moderate in severity (leading to the overnight hospitalization ofone patient), and most resolved within four days. Subsequently, the rates of adverse evenm were similar in the two groups. The frequencies of gastroin~stinal and renal or urinary disorders were similar in the two groups.
One patient in lhe risedronate group and one patient in the zoledronic acid group who had preexisting renal impairment had moderate increases in serum creatinine levels at two months and six months, respectively. The mean serum creatinine level had decreased slightly but significantly by day 10 in the zoledronic acid group, as compared with the risedronate group (-0.05±0.10 mg per deciliter The shaded areas represent:the normal ranges ire premenopv.uul women.
Hypocalcemia developed in eight patients in the zoledronlc acid group and was asymptomatic in six of these patients. The two patients with mild symptoms had not taken their calcium and vita.min D supplements. One patient in the risedronate group had severe symptomatic bypocalcemia, despit.e taking calcium and vitamin D suppletnent.s, and required hospitalization and intravenous calcium. All these events occurred during study days 3 through 13. There were decreases in serum calcium levels in both groups at day 10, but the decrease was larger in the zoledronlc acid group than the risedronate group (-0 
TRIAi. IHTENSION
Patients who met the definition ofa therapeutic response were eligible to enter a trial extension. A total of113 patienbi in the zoledronlc acid group and 82 in the risedronate group entered an open extension of the study, during which alkaline phosphatase was measured at six-month intervals. Ata median of 190 days after the end of the core study, 21 of82 patients in the risedronate group showed a loss of therapeutic response (25.6 percent), as compared with 1 of 113 patients in the zoledronic acid group (0.9 percent), a difference of96.5 per--cent (P<0.001).
DISCUSSION
This study demonstrates the safety and efficacy ofa single-dose therapy for Paget's disease. A single infusion of 5 mg of z.oledron.ic acid, given over a 15· minute period, produced changes in a variety of biochemical markers of djsease activity that appeared to be as great as or greater than the best resulbi achievable with conventional oml therapies, all of which require daily administration over pe- Data were analyzed by an analysls,of-(ovariance model with treatment. study. and1>ase.line ~co~ as explanatory variables. Oiff'ersnces within gr01.1p, were analyzed by a one•sample t-test No adjustments were made for m1:1ltiple comparisons. Multivariate testing (WIiies' lambda multivariate F-test) across the domains suggested the superiority,of zofed(onic atid (P-0.0S), as did similar testing across the two summa,y scores {P-0.04). A flve-point imp(ovement is generally c<msid-eA!d to be dlnically signific:1r1t, and the percentage of patients wlth at least this dtange at six months. i:s shown on the right for the gro11pJ. P values on the graph indicate significant differences from baseline, and P values ln parenthe.ses indicate significant differences between groups.
riods of up t.o six months. Unlike studies of other therapies for Paget's disease, we compared zoledronic acid directly with a bisphosphonate currently used as a standard therapy. Although our study was intended t.o demonstrate the noninferiority of zoledronic acid as compared with the conventional therapy, in fact, zoledronic acid appeared t.o be superior in terms of the degree of disease suppression, the rat:e of onset of effect, and (on the basis of preliminaiy data) the persistence of these effects beyond the six-month trial period. It is encouraging that the marlred biochemical effects of zoledronic acid appeared to be accompanied by significant improvements in indexes of the quality oflifc, including physical .functioning, pain, general health, vitality, and emotional welJ.being. The improvements in some of these indexes in the zoledconic acid group were significantly greater than those in the risedronate group. Although there is an issue regarding the use of multiple statistical t.ests on these numerous quality-of-life end points, it should be noted that all the domains showed a trend toward improvement with zoledronic acid therapy, which was not so for risedronate, suggesting that the significant results are not merely a statistical artifact. This suggests that the benefits observed in biochemical end points will ultimately result in greater clinical dividends among patients with Paget'sdiseasc, who may sometimes have substantial disability. In contrast, the currently used agents have not been d_ emonstrated to yield signif.. icant difrerences between groups in quality-of-life measures in randomized, controlled trials,J,4,11 even though the agents used for comparison wece placebo or the weak bisphosphonare etidronate.
Zoledronic acid has previously been studied in two preliminary trials involving patients with Paget's disease. In one, doses of24 to 400 µg were administered and biochemical end points followed for two weeks.17The highest of these doses e1used reductions in hydroxyproline of almost 50 percent, though, as expected, there was no effect on alkaline phosphatase levels during this brief period. A second study,1• 18 showed a halving of bone tumover markers 90 days after an infusion of 400 µg of zoledronic acid, with lesser responses to lower doses. Our findings confirm the efficacy of zoledronic acid in patients with Paget's disease and add sub-' stantiallyto the available data by demonstrating that prolonged remissions can be achieved, accompanied by improvements in the quality of life.
The magnitude and time course of the effect o f zoledronic acid are likely to result from its singledose administration, the drug's high affinity for bone mineral, and its potent inhibition of the putative target of nitrogen-containing bisphosphonates, the enzyme f.lrnesyl diphosphat.e syntbase. 1 9-2 2 The persistence ofits effect makes it a particularly suitable agent for the management of Paget's disease, in which the need for frequent re--treatment is a major clinical problem. Influenza-like symptorn,s are common after the intravenous administration of nitrogen-containing bisphosphonates, being reported in two thirds of patients receiving pamidronate for Paget's disease. 2 3, 2 4
Our .findings confirm the apparent renal safety of zoledronic acid in patients with non-neoplastic bone disease, 8 though it should be not.ed that only those with a baseline creatinine clearance great.er than 30 ml per minute were eligible, consistent with current dosing recommendations for oral bisphos· phonates. Asymptomatic hypocalcemia is common after the use ofintravenous bisphosphonates in pa· tients with Paget's disease23, 24 In conclusion, we found thata single infusion of zoledronic acid can produce rapid and sustained remissions, which appear to be accompanied by improvements in the quality of life. The long dura· tion of r~mission may result in more complete conttol of disease activity than has previously been possible.
